Axomadol (INN USAN; EN3324) is a synthetic centrally-acting analgesic which was under investigation by Endo Pharmaceuticals in collaboration with Grünenthal for the treatment of chronic moderate to severe lower back pain and arthrosis. Development was halted after phase II clinical trials as it did not meet the pre-determined clinical endpoints.
This page contains content from the copyrighted Wikipedia article "Axomadol"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
